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The efficacy-effectiveness gap in
PMTCT
To the Editor: I wish to congratulate Sherman et al.1 on having
undertaken the challenge of assessing the efficacy of a
prevention of mother-to-child transmission (PMTCT)
programme in a routine setting. The findings of the study are
groundbreaking in many ways. However, we feel that this
study partially fails to envelop the entire reality of PMTCT,
thus leading to a potentially misleading title and conclusion.
Selection bias and drop-out of the study population in addition
to the extrapolation of research setting rates to routine setting
ones call for caution when interpreting the study findings.
The efficacy of the single-dose nevirapine regimen has been
established by clinical trials.2,3 A reality perspective implies
assessment of the effectiveness of PMTCT for HIV-positive
women accessing routine care, rather than only for women
who gave consent for voluntary counselling and testing (VCT).
Therefore the VCT acceptability rate should have been
reported. In the Coronation Women and Children’s Hospital
(CWCH) area, with an estimated HIV prevalence rate in
pregnant women similar to that of Gauteng, approximately
2 450  of 8 221 women who gave birth were HIV-positive
(29.8%). Thus, 1 216 potential participants were never enrolled
in the PMTCT programme. Neither these women nor their
babies received nevirapine. Nor were counselling on infant
feeding choices or free milk formula provided. Even if this
‘forgotten group’ was counselled on infant feeding choices,
MTCT would occur in 20.7%, according to the findings of
Coutsoudis et al.4 on MTCT rate and infant feeding practices.4
Another concern is the assumption that drug compliance in
the group without records of nevirapine status is similar to that
of the group with properly recorded nevirapine status.
Although there is no hard evidence for reduced compliance in
the ‘no record’group (25%), there is no proof of equal
compliance in both groups either. It is not unthinkable that
drug administration may also be missed in an environment in
which registers are not kept properly, the latter owing to the
less stable and controlled environment of the labour ward. 
Similarly to the effectiveness of drug compliance, the
authors jump to the conclusion that the women from the
communities attending the routine PMTCT programme are
able to abstain from breast-feeding. Even though this statement
is confirmed in the ‘research group’, data on feeding practices
are missing for 38% of the women in the ‘routine setting’.
Women participating in the infant diagnostic study may have
felt more encouraged and supported to abstain from breast-
feeding than their counterparts in the routine setting. In
addition, the thought of having their babies tested for HIV at 6
weeks and 3 months of age may have been an extra stimulus to
formula-feed exclusively. Acknowledging the fact that both
follow-up infant visits and adherence to exclusive formula-
feeding require a certain level of commitment, selection bias
may be suspected with regard to the rates of reported feeding
practices. In other words, among those 38% lost to follow-up,
relatively more breast-feeding and mixed feeding may have
occurred. Moreover, feelings of fear or guilt that go along with
having breast-fed may have counteracted return for follow-up
infant visits. For the above reasons, the overall rate of exclusive
formula-feeding may be lower than assumed by Sherman et al.1
When considering the results of this study one should keep
in mind that the findings are merely efficacy rates for the
CWCH, so they do not necessarily reflect the real MTCT rate in
the community. As much as this study is a big leap forward in
the implementation of PMTCT, additional research is needed to
translate high levels of efficacy into equally high levels of
effectiveness in the community.
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Louis Leipoldt
To the Editor: South Africa has a dearth of good biographers
and Kay de Villiers1 has produced an unsentimental and
objective account of the luminary life of Louis Leipoldt, a
medical renaissance man.
One issue is conspicuous by its absence in the article —
Leipoldt’s sexuality. Dr Peter Shields, in the introduction to the
recent anthology,2 left no doubt that Leipoldt was homosexual,
although either inactive or highly discreet. I mention this not
out of a sense of scurrilous sensationalism but because any
account of Leipoldt that ignores it is lacking.
Consider the effect on someone who, by his own admission,
did medicine to expiate a sense of guilt engendered by being
the son of missionary. To what extent was his career choice
driven by a deeper guilt about sexuality? Leipoldt was a
remarkable doctor,  but what would he have achieved if he had
devoted himself to pursuits not driven by a sense of guilt and
desire to care for others?
And, on a positive note, as a genuine polymath and
sensualist, to what extent was his sensibility a reflection of a
more subtle homosexual perception for which we are all the
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